Търсене на изпитвания

AI · Cancer

Намерени 1,993 изпитвания за "Cancer" Стр. 80 от 100

Активно (без набиране) Фаза 2

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

Non Small Cell Lung Cancer Nonsquamous Non Small Cell Lung Cancer Squamous Non Small Cell Lung Cancer Lung Cancer

This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).

Начало: 08.02.2021 Край: 01.05.2027 Възраст: от 18 г.

Hong Kong, Malaysia, Philippines +7 Arcus Biosciences, Inc. NCT04736173

Активно (без набиране) Фаза 3

Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Breast Cancer

The purpose of this study is to find out whether a new drug, Ipatasertib, can slow the growth of advanced breast cancer when added to standard therapy (Fulvestrant).

Начало: 27.01.2021 Край: 31.12.2026 Възраст: от 18 г. Лечение

Australia, Canada, New Zealand Canadian Cancer Trials Group NCT04650581

Активно (без набиране) Фаза 2

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Ganglioneuroblastoma, Nodular Neuroblastoma

This phase II trial studies if dinutuximab, GM-CSF, isotretinoin in combination with irinotecan, and temozolomide (chemo-immunotherapy) can be given safely to patients with high-risk neuroblastoma after Consolidation therapy (which usually consists of two autologous stem cell transplants and radiation) who have not experienced worsening or recurrence of their disease. Dinutuximab represents a kind of cancer therapy called immunotherapy. Unlike chemotherapy and radiation, dinutuximab targets the cancer cells without destroying nearby healthy cells. Sargramostim helps the body produce normal infection-fighting white blood cells. Isotretinoin helps the neuroblastoma cells become more mature. These 3 drugs (standard immunotherapy) are already given to patients with high-risk neuroblastoma after Consolidation because they have been proven to be beneficial in this setting. Chemotherapy drugs, such as irinotecan and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. They may also affect how well immunotherapy works on neuroblastoma cells. Giving chemo-immunotherapy after intensive therapy may work better in treating patients with high-risk neuroblastoma compared to standard immunotherapy.

Начало: 31.12.2020 Край: 30.09.2027 Възраст: до 30 г. Лечение

Australia, Canada, New Zealand +1 Children's Oncology Group NCT04385277

Активно (без набиране) Фаза 2

Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer

Breast Cancer Breast Neoplasms

This is a Phase II, randomized, open-label trial to evaluate the clinical and immunologic activity of pembrolizumab plus chemotherapy when combined with various immunotherapy induction regimens as neoadjuvant therapy for triple negative breast cancer (TNBC).

Начало: 30.12.2020 Край: 01.12.2026 Възраст: от 18 г.

United States Providence Health & Services NCT04373031

Активно (без набиране) Фаза 3

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

Non-small Cell Lung Cancer

This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations.

Начало: 21.12.2020 Край: 15.02.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +23 Daiichi Sankyo NCT04656652

Активно (без набиране) Фаза 3

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Neoplasms

The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the potential treatment of colorectal cancer that: * has spread to other parts of the body (metastatic); * has a certain type of abnormal gene called "BRAF"; and * has not received prior treatment. Participants in this study will receive one of the following study treatments: * Encorafenib plus cetuximab: These participants will receive encorafenib by mouth at home every day and cetuximab once every two weeks by intravenous (IV) infusion (an injection into the vein) at the study clinic. * Encorafenib plus cetuximab with chemotherapy: These participants will receive encorafenib and cetuximab in the way described in the bullet above. Additionally, they will receive standard chemotherapy by IV infusion and oral treatment at home. * Chemotherapy alone: These participants will receive chemotherapy, the standard treatment for this condition, by IV infusion at the study clinics and oral treatment at home. This study is currently enrolling participants who will receive either encorafenib plus cetuximab with chemotherapy or chemotherapy alone. The study team will monitor how each participant responds to the study treatment for up to about 3 years.

Начало: 21.12.2020 Край: 28.12.2027 Възраст: от 16 г. Лечение

Argentina, Australia, Belgium +25 Pfizer NCT04607421

Активно (без набиране) Фаза 1

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer

DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other therapies in patients with Metastatic HER2-low Advanced or Metastatic Breast Cancer

Начало: 17.12.2020 Край: 16.06.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +7 AstraZeneca NCT04556773

Активно (без набиране) Фаза 3

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Lung Cancer, Non-Small Cell

This is a multi-center, parallel group treatment, Phase 2/3 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced non-small cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.

Начало: 08.12.2020 Край: 30.03.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +21 GlaxoSmithKline NCT04655976

Активно (без набиране)

Markerless Image Guidance Using Intrafraction Kolovoltage X-ray Imaging for Lung Cancer Radiotherapy

Lung Cancer Markerless Image Guidance Intrafraction Kolovoltage X-ray Imaging

In radiotherapy, tumour tracking allows us to ensure the radiation beam is accurately targeting the tumour while it moves in a complex and unpredictable way. Most tumour tracking techniques require the implantation of fiducial markers around the tumour. Markerless Tumour Tracking negates the need for implanted markers, enabling accurate and optimal cancer radiotherapy in a non-invasive way.

Начало: 04.12.2020 Край: 31.12.2027 Възраст: 18–80 г.

Australia Royal North Shore Hospital NCT04310891

Активно (без набиране) Фаза 1

Testing a New Imaging Agent to Identify Cancer

HER-2 Positive Malignant Carcinoma of Breast HER-2 Protein Overexpression HER2-positive Metastatic Breast Cancer

The purpose of this study is to see whether 89Zr-ss-pertuzumab is safe in people with HER2+ cancer.

Начало: 30.11.2020 Край: 30.11.2026 Възраст: от 18 г.

United States Memorial Sloan Kettering Cancer Center NCT04692831

Активно (без набиране) Фаза 3

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer

Lung Cancer, Non-Small Cell

This is a multicenter, randomized, double-blind, placebo-controlled study of niraparib plus pembrolizumab versus placebo plus pembrolizumab as maintenance therapy in participants with advanced or metastatic non-small cell lung cancer (NSCLC) who have achieved stable disease (SD), partial response (PR), or complete response (CR) following completion of standard of care first-line (SoC 1L) platinum-based induction chemotherapy with pembrolizumab. The primary hypotheses are: participants with confirmed diagnosis of NSCLC could benefit from niraparib plus pembrolizumab versus placebo plus pembrolizumab with respect to Progression-free survival (PFS) and Overall survival (OS).

Начало: 26.10.2020 Край: 06.03.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +23 GlaxoSmithKline NCT04475939

Активно (без набиране) Фаза 3

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Metastatic Prostate Cancer Prostate Adenocarcinoma

This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease.

Начало: 19.10.2020 Край: 16.10.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +22 Exelixis NCT04446117

Активно (без набиране) Фаза 3

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

Carcinoma, Non-Small-Cell Lung

The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.

Начало: 13.10.2020 Край: 02.08.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +22 Janssen Research & Development, LLC NCT04538664

Активно (без набиране) Фаза 3

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

This is a randomized, double-blind, multicenter, global Phase 3 study to assess the efficacy and safety of monalizumab and cetuximab, compared to placebo and cetuximab, in Participants with recurrent or metastatic head and neck cancer

Начало: 02.10.2020 Край: 24.09.2026 Възраст: 18–130 г. Лечение

Argentina, Australia, Belgium +18 AstraZeneca NCT04590963

Активно (без набиране) Фаза 3

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \[Exon 19del\] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).

Начало: 30.09.2020 Край: 30.11.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +25 Janssen Research & Development, LLC NCT04487080

Активно (без набиране) Фаза 3

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Metastatic Castration-sensitive Prostate Cancer

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus prednisone in participants with deleterious germline or somatic Homologous Recombination Repair (HRR) gene-mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) provides superior efficacy in improving radiographic progression-free survival (rPFS).

Начало: 23.09.2020 Край: 01.11.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Belarus +27 Janssen Research & Development, LLC NCT04497844

Активно (без набиране) Фаза 1

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Aggressive Variant Prostate Carcinoma Castration-Resistant Prostate Carcinoma Metastatic Clear Cell Renal Cell Carcinoma Metastatic Malignant Solid Neoplasm +6

This phase Ib trial studies the side effects and best dose of DS3201 when given together with and ipilimumab for the treatment of patients with prostate, urothelial, or renal cell cancer that has spread to other places in the body (metastatic). DS3201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving DS3201 and ipilimumab may help to control the disease.

Начало: 20.08.2020 Край: 31.12.2026 Възраст: от 18 г.

United States M.D. Anderson Cancer Center NCT04388852

Активно (без набиране) Фаза 3

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Advanced or Metastatic Breast Cancer

This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.

Начало: 24.07.2020 Край: 19.06.2026 Възраст: 18–105 г. Лечение

Argentina, Australia, Belgium +22 AstraZeneca NCT04494425

Активно (без набиране) Фаза 3

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

Hormone-Sensitive Prostate Cancer

This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency. The intention of the study is to demonstrate that in participants with mHSPC, the combination of capivasertib plus abiraterone (+prednisone/prednisolone) plus ADT is superior to placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC characterised by PTEN deficiency with respect to radiographic progression-free survival (rPFS) per 1) Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for soft tissue and/or Prostate Cancer Working Group (PCWG3) for bone as assessed by the investigator 2) death due to any cause.

Начало: 13.07.2020 Край: 29.03.2027 Възраст: 18–130 г. Лечение

Argentina, Australia, Belgium +28 AstraZeneca NCT04493853

Активно (без набиране) Фаза 2

Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

Breast Cancer

The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer.

Начало: 30.06.2020 Край: 01.12.2028 Възраст: от 18 г.

United States The Methodist Hospital Research Institute NCT03820141

1 … 78 79 80 81 82 … 100